CSIMarket
 


Gilead Sciences Inc   (GILD)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

GILD's EPS from Cont. Operations Growth by Quarter and Year

Gilead Sciences Inc 's EPS from Cont. Operations results by quarter and year




GILD EPS from Cont. Operations (in $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 1.23 2.13 -
III Quarter September - 0.29 -0.92 1.62
II Quarter June - -2.66 1.48 1.40
I Quarter March 1.38 1.23 1.55 1.18
FY   1.38 0.09 4.24 4.20



GILD EPS from Cont. Operations first quarter 2021 Y/Y Growth Comment
Gilead Sciences Inc achieved in the first quarter, above Company average EPS from Cont. Operations increase of 12.2% year on year, to $ 1.38 .

Among companies who have reported first quarter results in the Biotechnology & Drugs industry only one Company has achieved higher year on year EPS from Cont. Operations results in the first quarter. While Gilead Sciences Inc ' s EPS from Cont. Operations growth of 12.2% ranks overall at the positon no. 72 in the first quarter.




GILD EPS from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - -42.25 % - -
III Quarter September - - - -22.12 %
II Quarter June - - 5.71 % -40.43 %
I Quarter March 12.2 % -20.65 % 31.36 % -43 %
FY   - -97.88 % 0.95 % 18.64 %

Financial Statements
Gilead Sciences Inc 's first quarter 2021 EPS from Cont. Operations $ 1.38 GILD's Income Statement
Gilead Sciences Inc 's first quarter 2020 EPS from Cont. Operations $ 1.23 Quarterly GILD's Income Statement
New: More GILD's historic EPS from Cont. Operations Growth >>


GILD EPS from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 324.14 % - -
III Quarter September - - - 15.71 %
II Quarter June - - -4.52 % 18.64 %
I Quarter March 12.2 % -42.25 % - -
FY (Year on Year)   - -97.88 % 0.95 % 18.64 %




EPS from Cont. Operations first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #6
Overall #72

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
238.12 % 7.86 % -90.4 %
(Dec 31 2018)   (Dec 31 2020)
EPS from Cont. Operations first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #6
Overall #72
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
238.12 % 7.86 % -90.4 %
(Dec 31 2018)   (Dec 31 2020)

EPS from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Gilead Sciences Inc 's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
66601.67 % 1158.53 % -99.86 %
(Mar 31 2019)  


GILD's I. Quarter Q/Q EPS from Cont. Operations Comment
Gilead Sciences Inc achieved in the I. Quarter 2021 below company average EPS from Cont. Operations rise of 12.2% quarter on quarter, to $ 1.38 .

I. Quarter 2021 results seem to be a mixed bag, even if lower than the average, yet it shows absolute recovery relative to the -42.25% in the I. Quarter a year ago

Within Biotechnology & Drugs industry 4 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Gilead Sciences Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is 561.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #5
Healthcare Sector #35
Overall #561
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #5
Healthcare Sector #35
Overall #561
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
66601.67 % 1158.53 % -99.86 %
(Mar 31 2019)  


GILD's I. Quarter Q/Q EPS from Cont. Operations Comment
Gilead Sciences Inc achieved in the I. Quarter 2021 below company average EPS from Cont. Operations rise of 12.2% quarter on quarter, to $ 1.38 .

I. Quarter 2021 GILD's EPS from Cont. Operations sequential growth were a mixed bag, even if beneath the average rise of 1158.53 %, yet it shows absolute acceleration measured to the -42.25% in the I. Quarter a year ago

Within Biotechnology & Drugs industry 4 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Gilead Sciences Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is 561.


Gilead Sciences Inc 's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative EPS from Cont. Operations 12 Months Ending $ 0.24 $ 0.09 $ 0.99 $ -0.22 $ 3.92
Y / Y EPS from Cont. Operations Growth (TTM) -93.75 % -97.76 % -53.23 % - -14.31 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 1196 # 1122 # 1149 # 0 # 475
Seqeuential EPS from Cont. Operations Change (TTM) 158.11 % -90.4 % - - -7.55 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 72 # 1815 # 1231 # 0 # 493




Cumulative EPS from Cont. Operations growth Comment
Gilead Sciences Inc showed decline, but improvement compare to trailing twelve month EPS from Cont. Operations decrease in Dec 31 2020. If the fiscal year would end in Mar 31 2021, Gilead Sciences Inc 's annual EPS from Cont. Operations decrease would be -93.75% year on year to $0 .

In the Healthcare sector 81 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 1122 to 1196.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
238.12 %
7.86 %
-90.4 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 2
Healthcare Sector # 82
Overall # 1196

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
296.02 %
18.52 %
-97.76 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 6
S&P 500 # 72
Cumulative EPS from Cont. Operations growth Comment
Gilead Sciences Inc showed decline, but improvement compare to trailing twelve month EPS from Cont. Operations decrease in Dec 31 2020. If the fiscal year would end in Mar 31 2021, Gilead Sciences Inc 's annual EPS from Cont. Operations drop would be -93.75% year on year to $0 .

In the Healthcare sector 81 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 1122 to 1196.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
238.12 %
7.86 %
-90.4 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 2
Healthcare Sector # 82
Overall # 1196

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
296.02 %
18.52 %
-97.76 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 6
S&P 500 # 72




Other EPS from Cont. Operations Growth
Biotechnology & Drugs Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
GILD's EPS from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for GILD's Competitors
EPS from Cont. Operations Growth for Gilead Sciences Inc 's Suppliers
EPS from Cont. Operations Growth for GILD's Customers

You may also want to know
GILD's Annual Growth Rates GILD's Profitability Ratios GILD's Asset Turnover Ratio GILD's Dividend Growth
GILD's Roe GILD's Valuation Ratios GILD's Financial Strength Ratios GILD's Dividend Payout Ratio
GILD's Roa GILD's Inventory Turnover Ratio GILD's Growth Rates GILD's Dividend Comparisons



Companies with similar EPS from Cont. Operations drop for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Mar 31 2021
Ensign Group Inc19.74%$ 19.737 
Charles River Laboratories International inc 19.42%$ 19.417 
Davita Inc 18.48%$ 18.478 
Teva Pharmaceutical Industries Ltd16.67%$ 16.667 
Chemed Corporation16.57%$ 16.571 
Syneos Health Inc 15.63%$ 15.625 
Fitlife Brands Inc 14.71%$ 14.706 
Alexion Pharmaceuticals Inc 14.68%$ 14.683 
Gilead Sciences Inc 12.20%$ 12.195 
Vertex Pharmaceuticals Inc8.62%$ 8.621 
Molecular Templates Inc 6.25%$ 6.250 


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PULM's Profile

Stock Price

PULM's Financials

Business Description

Fundamentals

Charts & Quotes

PULM's News

Suppliers

PULM's Competitors

Customers & Markets

Economic Indicators

PULM's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071